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 Abstract 
 
Prediction Models and Pharmacogenomics in Adult Growth Hormone Deficiency 
 
Edna de Jesus Litenski Barbosa 
 
Department of Endocrinology, Institution of Internal Medicine, the Sahlgrenska Academy at the 
University of Gothenburg, Gothenburg, Sweden.  
 
The overall aim of this thesis was to study clinical and genetic factors that influence response to 
growth hormone replacement therapy (GHRT) in GH deficient (GHD) adults. The patients were part 
of a cohort of adults with hypopituitarism and severe GHD who were studied before and after 12 
months of GHRT. The dose regimen was individualized in order to attain normal IGF-I levels. 
Logistic regression (LR) analysis was used to identify good and poor responders to GHRT. The 
candidate gene approach was used to study single nucleotide polymorphisms (SNPs) in the GH 
receptor (GHR) gene, in genes related to GH signaling pathways, lipid metabolism and renal tubular 
function. Changes in IGF-I levels, body composition (BC), lipid profile and extracellular water (ECW) 
were analyzed as the GHRT outcomes. We identified gender and insulin levels at baseline as 
predictors for changes in IGF-I levels, and gender, height and lean body mass (LBM) at baseline as 
predictors for changes in BC. The accuracy of the equations obtained by LR to predict whether a 
patient will be a GR or PR was 70% for IGF-I and 80% for BC responses. The d3 allele polymorphism 
in the GHR gene did not influence IGF-I levels and BF at baseline and their changes after GHRT. At 
baseline, distinct SNPs of the cholesteryl ester transfer protein (CETP) gene were associated with 
higher total cholesterol (TC), HDL-C and LDL-C, those of the apolipoprotein E (APOE) gene with 
lower TC and LDL-C, APOB gene with higher serum HDL-C, and those of the peroxisome 
proliferator-activated receptor gamma (PPARG) gene with lower LDL-C and the APOE/C1/C4/C2 
cluster with lower tryglicerides (TG). After GHRT, greater reductions in TC and LDL-C were 
associated with SNPs in the APOB and PPARG, explaining 5% of the variation. SNPs in the signal 
transducer and activator of transcription 5B (STAT5B), in the phosphoinositide-3-kinase, catalytic, 
beta polypeptide (PIK3CB) and in the sodium/potassium/chloride transporter member 1 (SLC12A1) 
genes were associated with differences in ECW in GHD patients. We conclude that gender, body 
height, LBM and insulin levels were the best predictors of IGF-I and BC responses to GHRT in GHD 
adults. The presence of the d3-GHR allele did not influence responses to GHRT, but we found that 
some SNPs in genes related to lipid metabolism, GH signaling pathways and water balance impact the 
baseline characteristics of GHD and their response to GHRT. 
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